.png){kind=icon}
.png){kind=icon}
Return
Immunoregulatory protein-hybrid extracellular vesicles via self-loadable backbone cyclization for oral inflammatory bowel disease therapy
.png){kind=icon}
PRE
AI
Y
Y
K
O
C
J
J
P
D
Y
DOI：10.1016/j.bioactmat.2025.11.036.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Despite the potential of extracellular vesicles (EVs) and therapeutic proteins as carriers and cargos for oral delivery, their precise functional integration remains a persistent challenge, thereby limiting synergistic therapeutic outcomes. Here, we present a protein-hybrid, orally delivered EV strategy that integrates naturally bioactive EVs with self-loadable, backbone-cyclized immunoregulatory proteins for inflammatory bowel disease (IBD) therapy. Through computationally guided design and split intein-mediated backbone cyclization, we generated cyclized variants of key immunoregulatory proteins with improved functionality. Among these, C-R4-tagged cyclization of phosphatase domain of T-cell protein tyrosine phosphatase (ppTCPTP) improved membrane permeability, thermal stability, and anti-inflammatory activity. This backbone cyclization enabled efficient and high-capacity loading of ppTCPTP into native EVs that are not amenable to genetic engineering. Notably, these protein-hybrid EVs exhibited acidic resistance for oral delivery and synergistically enhanced antioxidant and anti-inflammatory effects in murine IBD organoids and in vivo colitis models, markedly reducing intestinal inflammation and restoring epithelial barrier integrity. Our findings highlight the translational potential of this self-loadable protein-EV platform as a safe and potent oral biologic for IBD therapy.
Keywords:
Extracellular vesicle
Protein cyclization
Oral delivery
Inflammatory bowel disease
T -cell protein tyrosine phosphatase
Anti-inflammation
Journal
IF:
20.3
Papers:
2.6K
Citations:
3.2W
Organization
Cited Papers